|
1
|
Herr MM, Torka P, Zhang Y, Wallace PK, Tario JD, Repasky EA, Chen GL, Ho CM, Balderman SR, Ross M, Paiva B, Hernandez-Ilizaliturri FJ, McCarthy PL, Hahn T. Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant. Bone Marrow Transplant 2019; 55:77-85. [PMID: 31227776 PMCID: PMC6925359 DOI: 10.1038/s41409-019-0591-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Revised: 04/23/2019] [Accepted: 04/27/2019] [Indexed: 12/03/2022]
Abstract
This is the first longitudinal study of immune profiles and autologous hematopoietic cell transplant (AHCT) survival in B-cell non-Hodgkin lymphoma (B-NHL) patients and the effect of plerixafor mobilization on immune reconstitution in this population. A comprehensive immunophenotyping panel was performed in 104 consecutive adult B-NHL patients (58% diffuse large B-cell, 42% mantle cell) who received AHCT (1/2008-11/2014), at a median of 28 days pre-AHCT (N=104) and Day+100 (N=83) post-AHCT. Median follow-up post-AHCT was 61 months (range: 8-120 months). Compared to patients mobilized with filgrastim and plerixafor, patients mobilized with filgrastim alone had a higher proportion of CD4+ naïve (p=0.006) and CD8+ central memory T-cells (p=0.006) pre-AHCT. For patients transplanted in complete remission (CR), a higher proportion of CD8+ effector memory T-cells pre-AHCT was associated with worse progression-free survival (PFS; p<0.01) and overall survival (OS; p<0.01). A higher ratio of CD8:CD4+ central memory T-cells pre-AHCT was associated with worse PFS (p<0.0001) and OS (p=0.0034). This same ratio measured post-AHCT among patients in CR on Day+100 was associated with worse and OS (p=0.008) but not PFS (p=not significant). These immune subsets are complementary biomarkers which identify patients transplanted in CR who have poor survival prognoses and may warrant further clinical interventions.
Collapse
Affiliation(s)
- Megan M Herr
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Pallawi Torka
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Yali Zhang
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Paul K Wallace
- Department of Flow & Image Cytometry, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Joseph D Tario
- Department of Flow & Image Cytometry, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Elizabeth A Repasky
- Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - George L Chen
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Christine M Ho
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Sophia R Balderman
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Maureen Ross
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Bruno Paiva
- Clínica Universidad de Navarra, Pamplona, Spain
| | - Francisco J Hernandez-Ilizaliturri
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.,Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Philip L McCarthy
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Theresa Hahn
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
| |
Collapse
|
|
2
|
Derenzini E, Casadei B, Broccoli A, Gandolfi L, Pellegrini C, Zinzani PL. Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission. Br J Haematol 2014; 166:625-8. [DOI: 10.1111/bjh.12894] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Enrico Derenzini
- Department of Experimental; Diagnostic and Specialty Medicine; S.Orsola-Malpighi Hospital; University of Bologna; Institute of Hematology and Medical Oncology “L. & A. Seragnòli”; Bologna Italy
| | - Beatrice Casadei
- Department of Experimental; Diagnostic and Specialty Medicine; S.Orsola-Malpighi Hospital; University of Bologna; Institute of Hematology and Medical Oncology “L. & A. Seragnòli”; Bologna Italy
| | - Alessandro Broccoli
- Department of Experimental; Diagnostic and Specialty Medicine; S.Orsola-Malpighi Hospital; University of Bologna; Institute of Hematology and Medical Oncology “L. & A. Seragnòli”; Bologna Italy
| | - Letizia Gandolfi
- Department of Experimental; Diagnostic and Specialty Medicine; S.Orsola-Malpighi Hospital; University of Bologna; Institute of Hematology and Medical Oncology “L. & A. Seragnòli”; Bologna Italy
| | - Cinzia Pellegrini
- Department of Experimental; Diagnostic and Specialty Medicine; S.Orsola-Malpighi Hospital; University of Bologna; Institute of Hematology and Medical Oncology “L. & A. Seragnòli”; Bologna Italy
| | - Pier Luigi Zinzani
- Department of Experimental; Diagnostic and Specialty Medicine; S.Orsola-Malpighi Hospital; University of Bologna; Institute of Hematology and Medical Oncology “L. & A. Seragnòli”; Bologna Italy
| |
Collapse
|
|
3
|
Derenzini E, Stefoni V, Maglie R, Casadei B, Pellegrini C, Broccoli A, Stefani G, Fanti S, Motta MR, Narducci R, Argnani L, Zinzani PL. Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. Biol Blood Marrow Transplant 2013; 19:1695-701. [DOI: 10.1016/j.bbmt.2013.09.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2013] [Accepted: 09/10/2013] [Indexed: 10/26/2022]
|
|
4
|
Zinzani PL. Autologous hematopoietic stem cell transplantation in Non-Hodgkin's lymphomas. Acta Haematol 2005; 114:255-9. [PMID: 16269866 DOI: 10.1159/000088416] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Early studies on high-dose therapy followed by autologous bone marrow transplantation demonstrated the safety and efficacy of this approach in non-Hodgkin's lymphoma (NHL). As the procedure became easier and safer with the introduction of peripheral blood progenitor cells instead of marrow, the popularity of this procedure declined. In the last decade, autologous hematopoietic stem cell transplantation has played an important role in front-line and salvage treatments of indolent and aggressive NHL.
Collapse
Affiliation(s)
- Pier Luigi Zinzani
- L. and A. Seràgnoli Institute of Hematology and Oncology, University of Bologna, Bologna, Italy.
| |
Collapse
|